Matches in Wikidata for { <http://www.wikidata.org/entity/Q37246445> ?p ?o ?g. }
- Q37246445 description "2016 թվականի հունվարին հրատարակված գիտական հոդված" @default.
- Q37246445 description "article científic" @default.
- Q37246445 description "article scientifique" @default.
- Q37246445 description "articolo scientifico" @default.
- Q37246445 description "artigo científico" @default.
- Q37246445 description "artículu científicu espublizáu en 2016" @default.
- Q37246445 description "bilimsel makale" @default.
- Q37246445 description "bài báo khoa học" @default.
- Q37246445 description "scientific article published on January 2016" @default.
- Q37246445 description "vedecký článok" @default.
- Q37246445 description "vetenskaplig artikel" @default.
- Q37246445 description "videnskabelig artikel" @default.
- Q37246445 description "vědecký článek" @default.
- Q37246445 description "wetenschappelijk artikel" @default.
- Q37246445 description "wissenschaftlicher Artikel" @default.
- Q37246445 description "наукова стаття, опублікована в січні 2016" @default.
- Q37246445 description "научни чланак" @default.
- Q37246445 description "مقالة علمية نشرت في يناير 2016" @default.
- Q37246445 name "Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran" @default.
- Q37246445 name "Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran" @default.
- Q37246445 name "Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII" @default.
- Q37246445 type Item @default.
- Q37246445 label "Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran" @default.
- Q37246445 label "Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran" @default.
- Q37246445 label "Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII" @default.
- Q37246445 prefLabel "Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran" @default.
- Q37246445 prefLabel "Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran" @default.
- Q37246445 prefLabel "Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII" @default.
- Q37246445 P1433 Q37246445-9B6C693B-1124-4B54-BC21-66F14328C733 @default.
- Q37246445 P1476 Q37246445-FC926533-B074-4994-ACDD-603297A1D326 @default.
- Q37246445 P2093 Q37246445-04992F82-6B36-4115-9117-E10B5E60F90F @default.
- Q37246445 P2093 Q37246445-05F8A6B4-9DE7-4B53-80D9-35606ED22436 @default.
- Q37246445 P2093 Q37246445-23BF96DF-D48F-425C-B1A7-514579F1B265 @default.
- Q37246445 P2093 Q37246445-3332ADBF-1DBE-4B9A-84F8-DC68A3E802CA @default.
- Q37246445 P2093 Q37246445-33E0E2EA-06AF-4D3A-A574-7C170A201B49 @default.
- Q37246445 P2093 Q37246445-5ADB771C-C1B9-49BC-BFB0-137924DED819 @default.
- Q37246445 P2093 Q37246445-6D3A7BC7-7A3A-426F-9AB8-7F4F939D123A @default.
- Q37246445 P2093 Q37246445-8DE1A5BD-E746-41D9-964C-2EF6FBA18089 @default.
- Q37246445 P2093 Q37246445-9995667F-A535-42D1-AD4B-50BC0D46EEF0 @default.
- Q37246445 P2093 Q37246445-9C0FBE26-7575-4A80-8916-7C27979EFD5C @default.
- Q37246445 P2093 Q37246445-A16D160B-1E23-4C3F-93E2-FB74B6102D69 @default.
- Q37246445 P2093 Q37246445-BD9AAE8E-C215-458A-9FEF-699224F6AE3B @default.
- Q37246445 P2093 Q37246445-BF2203D4-C480-4A15-97A6-B77B56894918 @default.
- Q37246445 P2860 Q37246445-0269AF63-F460-4676-BDB6-F20CA1D079F8 @default.
- Q37246445 P2860 Q37246445-06E08F9D-DBF0-4E23-860C-621C159D6261 @default.
- Q37246445 P2860 Q37246445-1479C816-DCC2-4D4D-BF74-3C612E9DD43E @default.
- Q37246445 P2860 Q37246445-4CEF6E5C-7555-44A7-9E8F-440F0ADDA9B7 @default.
- Q37246445 P2860 Q37246445-4FE3319E-CE86-49A8-8D14-D78BD9033717 @default.
- Q37246445 P2860 Q37246445-5A1B6C7C-5CF7-4A0E-9B9B-B24C181F4339 @default.
- Q37246445 P2860 Q37246445-6FB34338-50F3-4D34-8E84-F48EAD34B6EB @default.
- Q37246445 P2860 Q37246445-846B470A-BEC0-418D-9D15-E3BDB1FF02CC @default.
- Q37246445 P2860 Q37246445-9B18A10E-CFF6-46AD-B6B9-D1A6AFB4AE40 @default.
- Q37246445 P2860 Q37246445-A48D3AF8-D26F-42A6-8924-64D6529DFBE4 @default.
- Q37246445 P2860 Q37246445-B3A908A7-B335-404A-A83E-40D936034760 @default.
- Q37246445 P2860 Q37246445-B5CC9284-1BB9-4411-9CAD-EB88F10B9E31 @default.
- Q37246445 P2860 Q37246445-DD1CD59E-25A0-4B33-85C6-5605AD7FC5F1 @default.
- Q37246445 P2860 Q37246445-DEDA58C9-C4D8-4F1B-B22D-C85ECB6C8F2F @default.
- Q37246445 P2860 Q37246445-E16D3A5D-21F6-4A5F-AAAC-6F06C66357C3 @default.
- Q37246445 P2860 Q37246445-EBBDC7DF-4B36-422F-AB34-EA836A9F9D5A @default.
- Q37246445 P2860 Q37246445-EC66EE1C-743F-443B-B10E-697436F457D6 @default.
- Q37246445 P304 Q37246445-563F98EC-3523-4B8B-8807-F7243ED2E19F @default.
- Q37246445 P31 Q37246445-22808641-0ABE-454F-AF87-4C6E6C8B79AA @default.
- Q37246445 P433 Q37246445-79934F47-BCB6-435A-9C60-F04D033BF2BB @default.
- Q37246445 P478 Q37246445-864D5978-97B3-4430-BF32-52DBDE43E3DA @default.
- Q37246445 P577 Q37246445-33983547-3A8A-4024-8FB1-94D15CB9A0BC @default.
- Q37246445 P698 Q37246445-F9858648-BB9A-49D5-B2BF-5B086984D2E4 @default.
- Q37246445 P921 Q37246445-561C01B9-BEC9-4DEA-A2A0-3D70F510B552 @default.
- Q37246445 P921 Q37246445-8815A7CD-169B-4302-A724-1719B9674424 @default.
- Q37246445 P932 Q37246445-4D1042FF-870D-4340-A0B3-AD5447BEE34E @default.
- Q37246445 P698 27642341 @default.
- Q37246445 P1433 Q20183787 @default.
- Q37246445 P1476 "Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran" @default.
- Q37246445 P2093 "Abdoll Majid Cheraghali" @default.
- Q37246445 P2093 "Ali Imani" @default.
- Q37246445 P2093 "Behnaz Habibpanah" @default.
- Q37246445 P2093 "Gholam Reza Toogeh" @default.
- Q37246445 P2093 "Hamid Hoorfar" @default.
- Q37246445 P2093 "Hamid Reza Rasekh" @default.
- Q37246445 P2093 "Jamshid Salamzadeh" @default.
- Q37246445 P2093 "Majid Naderi" @default.
- Q37246445 P2093 "Mina Golestani" @default.
- Q37246445 P2093 "Mohammad Reza Managhchi" @default.
- Q37246445 P2093 "Mohammad Taghi Khodayari" @default.
- Q37246445 P2093 "Peyman Eshghi" @default.
- Q37246445 P2093 "Razieh Hantooshzadeh" @default.
- Q37246445 P2860 Q28081532 @default.
- Q37246445 P2860 Q36564693 @default.
- Q37246445 P2860 Q37618924 @default.
- Q37246445 P2860 Q37687207 @default.
- Q37246445 P2860 Q37768481 @default.
- Q37246445 P2860 Q42598903 @default.
- Q37246445 P2860 Q45854920 @default.
- Q37246445 P2860 Q45859618 @default.
- Q37246445 P2860 Q45861916 @default.
- Q37246445 P2860 Q45863434 @default.
- Q37246445 P2860 Q45871197 @default.
- Q37246445 P2860 Q45882443 @default.
- Q37246445 P2860 Q45883316 @default.
- Q37246445 P2860 Q53940134 @default.
- Q37246445 P2860 Q73553840 @default.